Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




ctDNA-Based Liquid Biopsy Test Screens for 10 Common Cancers in Single Blood Draw

By LabMedica International staff writers
Posted on 11 May 2023

As the elderly population increases, there's an escalating crisis in cancer, with new cases being reported in the millions annually. More...

The shortfall in screening resources and poor adoption of conventional cancer screening methods result in most patients being diagnosed at advanced stages. Detecting cancer early, when it is still highly treatable, can avert unnecessary deaths due to the disease. A pioneering multi-cancer early detection (MCED) test now offers the potential for early cancer detection by screening for the risk of up to 10 cancers in a simple blood draw.

Lucence Health (Palo Alto, CA, USA) has introduced LucenceINSIGHT, a ctDNA-based liquid biopsy test capable of screening for 10 common cancers with a single blood draw. It is important to note that 78% of global cancer deaths are attributable to cancers for which there is no routine screening recommended. Blood testing could render the screening of various cancer types more accessible and convenient for people without symptoms.

LucenceINSIGHT identifies cancer-linked changes in DNA fragments found in the blood. These fragments, also referred to as circulating tumor DNA or ctDNA, are released into the bloodstream from cancer cells. Sophisticated sequence analysis is employed by the test to predict the site of origin. Results are presented as areas of concern, which healthcare providers may choose to investigate further if needed. Utilizing Lucence's unique next-generation sequencing technology, LucenceINSIGHT screens for cancer risks with a sensitivity rate of 73% and a specificity rate of 96%.

“Our mission is early cancer detection through a single blood test, when cancer is most treatable hopefully for cure,” said Lucence CEO and Medical Director Dr. Min-Han Tan. “We strongly believe in collaboration with partners who are motivated to overcome cancer together globally.”

Related Links:
Lucence Health 


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.